Addressing symptom burden in myeloproliferative neoplasms
Douglas Tremblay1, Ruben Mesa2
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Best Practice & Research. Clinical Haematology
|November 4, 2022
Summary
Myeloproliferative neoplasms (MPNs) cause severe symptoms impacting quality of life. Current treatments, including JAK inhibitors, effectively reduce symptom burden, with ongoing research for novel therapies.
Area of Science:
- Hematology
- Oncology
- Patient-Reported Outcomes
Background:
- Myeloproliferative neoplasms (MPNs) are associated with debilitating constitutional symptoms.
- Symptom burden in MPNs significantly impacts patient quality of life, comparable to metastatic solid tumors.
Purpose of the Study:
- To review the pathogenesis and assessment of constitutional symptoms in MPNs.
- To detail current and emerging therapies for managing MPN symptom burden.
Main Methods:
- Literature review focusing on symptom assessment tools and therapeutic interventions for MPNs.
- Analysis of pharmacologic (e.g., JAK inhibitors) and non-pharmacologic therapies.
Main Results:
- Validated patient-reported outcome tools, such as the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score, are available for symptom assessment.
- JAK inhibitors demonstrate efficacy in reducing symptom burden for myelofibrosis, polycythemia vera, and essential thrombocythemia.
Conclusions:
- Effective therapies exist for MPN symptom management, including JAK inhibitors and non-pharmacologic approaches.
- Further research is needed to address unmet needs in symptom assessment and treatment for MPNs.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
01:24Nephrotic Syndrome III : Nursing Management
30
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
30
01:26Nephrotic Syndrome II : Assessment and Medical Management
16
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
16